- Report
- June 2023
- 186 Pages
Global
From €5288EUR$5,500USD£4,537GBP
- Report
- December 2023
Global
From €7212EUR$7,500USD£6,187GBP
- Report
- June 2022
- 257 Pages
Global
From €5048EUR$5,250USD£4,331GBP
- Report
- April 2023
- 120 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Report
- January 2023
Global
From €7212EUR$7,500USD£6,187GBP
- Report
- August 2020
- 142 Pages
Global
From €4327EUR$4,500USD£3,712GBP
- Book
- October 2019
- 632 Pages
- Book
- January 2016
- 368 Pages
- Book
- August 2011
- 572 Pages
Endometrial cancer is a type of cancer that affects the lining of the uterus. It is the most common gynecologic cancer in the United States, and is typically diagnosed in women over the age of 50. Symptoms of endometrial cancer include abnormal vaginal bleeding, pelvic pain, and pain during intercourse. Treatment options for endometrial cancer include surgery, radiation therapy, chemotherapy, and hormone therapy.
The oncology market for endometrial cancer is highly competitive, with a range of treatments available. Pharmaceutical companies are developing new drugs to target endometrial cancer, and medical device companies are developing new technologies to improve diagnosis and treatment. Additionally, research is being conducted to better understand the biology of endometrial cancer and to develop new treatments.
Companies in the endometrial cancer market include AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more